The GSK3A Knockout DLD-1 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal cell population derived from the DLD-1 human colorectal adenocarcinoma line. This mixed pool contains cells harboring diverse GSK3A gene disruptions introduced by targeted Cas9 nuclease activity, resulting in a robust loss-of-function model without the need for single-cell cloning. The polyclonal format preserves natural genetic heterogeneity, making it well-suited for bulk functional genomics and pooled screening applications.
The parental DLD-1 cell line was established from a male colorectal adenocarcinoma patient and is a widely employed model in colorectal cancer research. DLD-1 cells carry a heterozygous APC mutation that partially activates Wnt/beta-catenin signaling, creating a sensitized background for assessing modulations of downstream components like GSK3A. They exhibit epithelial morphology and rapid proliferation, offering a convenient platform for cell signaling studies, drug sensitivity testing, and metabolic analyses.
GSK3A encodes glycogen synthase kinase 3 alpha, a serine/threonine kinase that acts as a central negative regulator of both Wnt/beta-catenin signaling and glycogen metabolism. It is inactivated through AKT-mediated phosphorylation downstream of PI3K and insulin stimulation, and is sequestered into the Axin/APC destruction complex upon Wnt ligand binding to Frizzled/LRP5/6 receptors via DVL and GBP. Active GSK3A phosphorylates beta-catenin to promote its proteasomal degradation and phosphorylates glycogen synthase to suppress glycogenesis, while also destabilizing transcription factors c-MYC and cyclin D1. Consequently, GSK3A knockout in this model relieves these inhibitory checkpoints, leading to constitutive TCF/LEF-mediated transcription and altered glycogen synthesis.
In the DLD-1 colorectal adenocarcinoma context, loss of GSK3A function is expected to further amplify Wnt pathway output, driving enhanced expression of proliferation-associated target genes and potentially increasing tumorigenic properties. This model therefore enables detailed examination of the crosstalk between hyperactive Wnt signaling and other oncogenic pathways, such as the PI3K/AKT/mTOR axis, and provides a tool for investigating metabolic reprogramming in cancer cells.
Research applications for this knockout pool include mechanistic studies of Wnt signal transduction, colorectal cancer drug screening, and metabolic flux profiling. Common assays involve western blotting to confirm GSK3A protein depletion, RT-qPCR for transcript-level validation, RNA-seq for global transcriptome analysis, beta-catenin reporter assays, immunofluorescence for beta-catenin localization, cell proliferation and colony formation assays, and drug sensitivity evaluations. The heterogeneous knockout background also supports pooled CRISPR screens. For additional technical details, please contact Ascent Research.
